Objective. This study explored the role of the adipokine adipsin in OA. Methods. Control and OA articular tissues, cells and serum were obtained from human individuals. Serum adipsin levels of human OA individuals were compared with cartilage volume loss as assessed by MRI at 48 months. Human adipsin expression was determined by PCR, its production in tissues by immunohistochemistry, and in SF and serum by a specific assay. OA was surgically induced in wild-type (Df +/+ ) and adipsin-deficient (Df À/À ) mice, and synovial membrane and cartilage processed for histology and immunohistochemistry.
Introduction
OA is characterized by a dysregulation of a number of molecules resulting in the degradation of the cartilage matrix. The mechanisms responsible are not completely understood, although major risk factors including age, female gender and obesity are recognized.
Adipose tissue-derived molecules such as adipokines have emerged as a novel group of mediators of metabolic processes that contribute to the progression and severity of OA. Elevated levels of some adipokines in the serum and SF of OA patients have been found to be associated with cartilage damage and volume loss [110] . One such adipokine, adipsin (complement factor D), has recently been shown to be present [11, 12] and involved in OA [13] . Adipsin is an integral component of the alternative complement pathway [14, 15] . This adipokine was first identified as a product of adipose tissue [14, 1618] , but has since been found to be produced in monocytes/ macrophages [14] , synovial macrophages [19] and more recently in the infrapatellar fat pad [20] .
Adipsin-deficient (Df À/À ) mice show no apparent abnormality in development and, when fed a regular diet, there is no difference in weight, concentration of triglycerides, cholesterol or free fatty acids between the wild-type (Df +/+ ) and the Df À/À mice [15, 21] . In OA, there have been few reports on adipsin. This adipokine was found to be present in a proteome [11] and a gene profiling [12] study, in which its levels in serum and cartilage from OA patients were higher than in non-OA specimens. Our group recently reported, using symptomatic OA patients from a clinical trial, that the serum level of adipsin was highly associated with cartilage volume loss and could serve as a predictor of cartilage destruction and total knee replacement [13] . Moreover, although not in an OA model, Df À/À mice subjected to immune complex-induced arthritis showed decreased disease incidence and clinical disease activity compared with the Df +/+ [22] , resulting from a deficiency in the alternative complement pathway [23] . However, as adipsin could be merely a marker of activated macrophages and fat pad, further studies are needed to clarify its presence, involvement and effect in OA articular tissues. This study thus aimed to (i) investigate the adipsin expression/production in human serum and articular tissues and cells; (ii) confirm its involvement in cartilage volume loss in human knee OA; and (iii) explore the in vivo effect of adipsin deficiency in OA synovial membrane and cartilage.
Methods

Specimen selection
Human control serum samples were obtained from individuals with no history of joint disease. Human control knee articular tissues were obtained within 12 h of death from individuals that had no history of joint disease and died of causes unrelated to arthritic diseases. Human OA serum samples were from the Montreal Rheumatology Institute and the Osteoarthritis Initiative (OAI) Progression subcohort. Human OA articular tissues were obtained from patients undergoing total knee arthroplasty. The Institutional Ethics Committee Board of the University of Montreal Hospital Research Centre approved the use of the serum and human articular tissues, and patients signed informed consent. Articular cells were released from cartilage, synovial membrane and subchondral bone by sequential enzymatic digestion at 37 C, as previously described [24, 25] . Only first-passaged chondrocytes and osteoblasts and third-passaged synoviocytes were used. See 'Specimen selection' section of the supplementary data, available at Rheumatology online.
RNA extraction and real-time PCR Total RNA was extracted, quantified and treated with DNase as described [26] . Real-time PCR was done with the SYBR Green PCR Master Mix (Qiagen, Valencia, CA, USA) [27] . See 'RNA extraction and real-time PCR' section of the supplementary data, available at Rheumatology online.
Measurement of adipsin production levels
Adipsin levels in human serum and SF were quantitated by a specific assay (Milliplex MAP kit, EMD Millipore Corp., Billerica, MA, USA) according to the manufacturer's specifications. In the fluids, the levels of adipsin (dilution 1:3000) were quantitated by Luminex technology using the LiquiChip 200 apparatus (Qiagen, Toronto, ON, Canada) and the data analysis performed with the LiquiChip Analyzer software (Qiagen). The minimal detectable value for adipsin is 0.116 ng/ml. Serum adipsin levels from Df +/+ and Df À/À mice were monitored by western blotting with serum diluted 1:4 in sample buffer, as described [28] . See 'Western blotting' section of the supplementary data, available at Rheumatology online.
MRI cartilage assessment MRI cartilage assessment was done on the OA patients from the OAI Progression subcohort. Knee MRI acquisitions were performed at baseline and at 48 months followup using double echo steady state imaging, as defined by the OAI protocol. Cartilage volume was measured using automatic human knee cartilage segmentation (ArthroLab Inc., Montreal, QC, Canada) as previously described and validated [29, 30] . Cartilage volume was analysed in the global tibiofemoral knee and the medial and lateral compartment subregions. The cartilage volume change over time was assessed as previously described [29, 30] . See 'MRI cartilage assessment' section of the supplementary data, available at Rheumatology online.
Clinical and radiographic data were obtained from the OAI database (http://www.oai.ucsf.edu). The knee diameter was measured in the mediolateral plane regularly, using digital calipers (model 2071M: Mitutoyo Corp., Kawasaki, Japan) as described [32] .
Histology
Ten weeks post-surgery, DMM-and sham-operated as well as non-operated (20-week-old) control mice were sacrificed by pentobarbital sodium. The right knees were embedded in paraffin and sections (5 mm) deparaffinized and processed as described [32] ; sections were evaluated by two independent readers (G.V.-F., F.P.) in a blinded fashion. See 'Histology' section of the supplementary data, available at Rheumatology online.
Synovial membrane
Histomorphometric quantitative analysis of the anterior synovial membrane thickness was performed on images captured at Â63 with a Leitz Diaplan microscope (Leica Microsystems, Wetzlar, Germany) coupled to a personal computer and histomorphometric data determined with Bioquant OSTEO MIR image analysis software, version 12.5.60 (Bioquant, Nashville, TN, USA); data are expressed as micrometres. Three sections were made from each block and each slide was examined.
Cartilage
The histological scoring method of the Osteoarthritis Research Society International was used to determine the extent of cartilage degradation [33] .
Cartilage collagen organization was evaluated on paraffin sections (5 mm) following Sirius red staining under polarized light microscopy as previously described [34] . See 'Histology' section of the supplementary data, available at Rheumatology online.
Immunohistochemistry
Synovial membrane and cartilage immunohistochemistry were performed on paraffin sections (5 mm); positive cells and cartilage pericellular and matrix staining from each specimen were quantified as described [24, 26, 3436] . Control procedures were performed by omission of the primary antibody and replacement of the primary antibody with a non-specific rabbit IgG (Santa Cruz Biotechnology, Dallas, TX, USA), which was used at the same concentration as the primary antibody. Controls showed only background staining (refer to supplementary Fig. S1 , available at Rheumatology online). See 'Immunohistochemistry' section of the supplementary data, available at Rheumatology online.
Statistical analysis
Values are expressed as mean (S.E.M.) or as mean (S.D.) as indicated. Differences between groups were assessed using the Student's t test or the MannWhitney test if non-normal distribution for continuous variables. Univariate correlations between adipsin level and cartilage change over time were carried out using Pearson's parametric correlation test since the data were normally distributed. This was done to assess whether the baseline levels of adipsin predicted cartilage change over time. Since in the previous study [13] data showed that the highest tertile of baseline adipsin levels significantly and independently predicted more cartilage volume loss in knee OA and according to the univariate analyses findings (refer to Results section), here we also elected to stratify the study population based on the highest tertile values of baseline adipsin to investigate the association with high (5median) cartilage volume loss at 48 months. Logistic regression adjusting for age, gender and BMI was used in which the dependent variable was the cartilage volume change at 48 months and the independent variable the baseline adipsin.
All tests were two-sided and a P < 0.050 was considered statistically significant. All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, NC, USA).
Results
Higher expression/production of adipsin in human OA serum, and articular tissues and cells Significantly higher adipsin levels were found in the serum (P = 0.027) and SF (P = 0.005) of OA patients (Fig. 1A) . To determine the articular source of the adipsin increase in the OA fluids, quantification of the expression of adipsin in human synovial membranes, chondrocytes, synoviocytes and osteoblasts was carried out. Data (Fig. 1B) showed that synovial membranes and chondrocytes expressed high levels of adipsin, but the expression in synoviocytes and especially osteoblasts was at a low level. There was no difference between OA and controls for the studied articular cells, but a trend toward statistical significance was found for the synovial membranes (P = 0.057).
As adipsin is expressed in higher amounts in OA synovial membrane compared with controls, we evaluated its production and location in this tissue by immunohistochemistry (Fig. 1CE) . In OA, adipsin was found at a significantly higher level in the lining (P = 0.011; Fig. 1C ), the infiltrated cells (Fig. 1D ) and the adipose cells (P = 0.040; Fig. 1E ). These results are not surprising as the synovial lining is thicker in OA compared with controls and, as is well known, the synovial lining is composed of cells from different origins (fibroblast-like and macrophage-like). Since adipsin is part of the complement pathway, we next looked at the production levels and location of an activated downstream complement component, C5b-9 (Fig. 1F ). C5b-9 was barely detectable in the control synovial membrane, while in OA it was observed in the lining cells, mostly in the sublining around the microvasculature adjacent to small inflamed infiltrates as previously described [37, 38] . In addition, we also examined adipsin and C5b-9 production and location within the cartilage using immunohistochemistry (Fig. 1G and H) . Data revealed that adipsin was found in both control and OA cartilage in the matrix as well as at the periphery of the chondrocytes (also named chondrons), mostly in the upper third of the control cartilage tissue and throughout the OA cartilage tissue. Both components displayed a significant increase in OA (P 4 0.002). The location of C5b-9 in OA cartilage was, as observed for adipsin, in the matrix and pericellular. However, in contrast to adipsin, in OA C5b-9 was found mostly in the upper level, and in control cartilage exclusively at the cartilage surface. Both positive pericellular and matrix staining were significantly increased in OA cartilage compared with controls (P = 0.002).
Human serum adipsin levels are associated with cartilage volume loss Human OA serum was obtained from the OAI Progression subcohort, in which the individuals had symptomatic radiographic OA and had undergone MRI at baseline and 48 months. The patients' characteristics at baseline are listed in Table 1 and represented an OA population at a mild-to-moderate stage of the disease. Compared with OA patients from clinical trials (moderate-to-severe disease severity), in this cohort individuals had lower WOMAC scores and KellgrenLawrence grades, and higher joint space width and cartilage volume at baseline. The cartilage volume loss at 48 months was similar to that of OA patients from clinical trials at 24 months [13] . Univariate analysis revealed that higher baseline values of adipsin were associated with greater cartilage volume loss in the lateral compartment [correlation coefficient (R) = À0.150; 95% CI: À0.292, À0.002; P = 0.047]. Of note, the negative correlation indicates that higher baseline adipsin values are associated with greater cartilage volume loss. No statistical significance was reached for the global knee or the medial compartment. Thus, as the higher baseline values of adipsin were associated with greater cartilage volume loss in the lateral compartment, we further evaluated, using logistic regression, the impact of the high level of adipsin (highest tertile) to predict high percentage of cartilage volume loss in the patients that progressed (% 5 median; patients who presented the greatest progression), as in the previous report [13] , adjusted for age, gender and BMI. Data showed (Table 2) a statistically significant correlation with the lateral compartment (odds ratio = 2.04; 95% CI: 1.02, 4.11; P = 0.045). 
FIG. 1
Adipsin expression and production in human serum, articular tissues and cells and C5b-9 production in articular
Morphometric assessment
Five-day-old (P5), P15 and 10-week-old Df À/À mice showed no differences in body size, weight or gross appearance when compared with Df +/+ mice, as previously reported [21, 22] (data not shown).
Knee joint swelling
To determine whether adipsin impacted the OA knee joint, OA was surgically induced (DMM) in Df +/+ and Df À/À mice. Monitoring of the knee joint swelling by measuring the diameter of the operated (right) knee showed that the initial swelling in both Df +/+ and Df À/À mice receded similarly (see supplementary Fig. S3 , available at Rheumatology online).
Preserved synovial membrane and cartilage integrity and decreased complement activity in OA-Df À/À mice We further looked at the effect of adipsin deficiency in mouse synovial membrane and cartilage.
Synovial membrane
Histomorphometric evaluation of the synovial membrane thickness ( Fig. 2A) in the Df +/+ mice comparing OA (DMM) with controls [i.e. not having undergone surgery (20 weeks old, non-operated) or a sham operation (20 weeks old, 10 weeks post-surgery)] revealed a significant increase (P 4 0.024). However, synovial membrane thickness of the DMM-Df À/À mice was comparable to that of controls, with a significance of P = 0.026 when compared with DMM-Df +/+ .
To explore whether adipsin deficiency altered the alternative complement pathway activation during the OA process, the production of the terminal complement effector C5b-9 was determined. Data revealed that the localization of C5b-9 in the DMM synovial membrane was as observed in humans, and with significantly reduced levels in DMM-Df À/À mice ( Fig. 2B ; P = 0.036) when compared with DMM-Df +/+ .
Cartilage
The cartilage integrity in the medial tibial plateaus and femoral condyles at 10 weeks post-DMM surgery as assessed histologically (Fig. 3A) showed no true differences between Df +/+ and Df À/À non-and sham-operated mice. However, as expected, DMM mice had a significantly https://academic.oup.com/rheumatology increased loss of cartilage structure compared with the non-or sham-operated mice on both tibial plateaus (Df +/+ , P 4 0.028; Df À/À , P 4 0.048) and femoral condyles (Df +/+ , P 4 0.024; Df À/À , P 4 0.013). Comparison between DMM-Df +/+ and DMM-Df À/À mice showed significantly less cartilage degradation in DMM-Df À/À mice in both compartments (P 4 0.026).
To substantiate the cartilage histological data, we further assessed the production of known biochemical and proteolytic markers (Fig. 3BE) . Compared with DMM-Df
DMM-Df
À/À mice displayed significantly reduced levels of aggrecan fragments ( Fig. 3B ; P = 0.041), type II collagen organization ( Fig. 3C ; P = 0.047) and degradation products ( Fig. 3D ; P = 0.039), as well as the protease MMP-13 ( Fig. 3E ; P = 0.012). As observed for the synovial membrane, the cartilage of DMM-Df À/À mice displayed significantly reduced levels of C5b-9 ( Fig. 3F ; P = 0.005) when compared with DMM-Df +/+ . Interestingly, as with human OA cartilage, we also observed a pericellular location for C5b-9 in DMM cartilage ( Fig. 3F inset, in the DMM-Df 
Discussion
This study is the first to demonstrate the in vivo role of adipsin in OA as a factor contributing to knee tissue degradation and strongly suggests that this adipokine is a potential therapeutic target for this disease. First, findings from an in vivo study confirm and complement previous findings showing that in human OA, the increased serum levels of adipsin are associated with OA [11] and cartilage volume loss over time [13] . Moreover, by using a mouse model, in vivo data showed that the lack of adipsin in OA markedly reduces both the synovial membrane and cartilage alterations. As an emerging finding, data also revealed that, in vivo, adipsin likely contributes to OA pathophysiology through its role as a component of the alternative complement pathway.
The significant association between higher serum levels of adipsin and increased cartilage volume loss in the lateral compartment over time in human knee OA confirms a previous study [13] using OA patients from a clinical trial, in which the disease severity was more advanced than that of the participants in the OAI cohort. Although, and as indicated in the previous study [13] , the exact reason for adipsin affecting the knee cartilage in the lateral compartment is at present unknown, such a favoured knee location (the lateral compartment) was also observed for other products' effects [39, 40] . It is noteworthy that the lateral compartment of the knee generally has less severe cartilage damage than, for example, the medial compartment. Thus, this finding likely reflects the effect of adipsin on less advanced OA cartilage lesions, agreeing with the data using the OA mouse model, as this model represents a mild-to-moderate stage of OA. Since in less advanced cartilage alterations there is a breakdown of the collagen meshwork and increased collagen anabolism and chondrocyte metabolism, it is possible that in such cartilage, the complement factors could have better diffusion and, importantly, substrate presence than in more severe cartilage lesions, and thus the higher adipsin activity. This study was the first to show that human OA synovial membrane and cartilage expressed higher levels of adipsin than their controls, in contrast to articular cells whose expression levels were similar in control and OA. This indicates that the increased presence of adipsin in the SF and cartilage likely results from the higher levels released from the OA synovial membrane, as an increased level of adipsin is found in this diseased tissue. This agrees with the data showing that adipsin-deficient mice did not display OA-induced increased thickness of the synovial membrane. Alternatively, but not exclusively, the increased adipsin level in articular tissues and serum could also originate from the infrapatellar fat pad. This is a possibility as it has been reported that the OA infrapatellar fat pad induces inflammatory and proteolytic markers such as COX-2 and MMP-13 in articular cells, but that neither of the well-known adipokines leptin and adiponectin were involved [41] . It is thus tempting to speculate that there is an increased production of adipsin released by the infrapatellar fat pad that could, at least in part, be responsible for the described higher activity in the cartilage. However, the association between the infrapatellar fat pad and adipsin needs to be further studied in detail.
As mentioned, adipsin is a key player in the alternative complement pathway. It is secreted as an inactive molecule that appears to remain at the periphery of the cells. When the complement pathway is activated, a proteolytic complex formed by the interaction of C3b, factor Bb and adipsin cleaves C3 into two fragments: the anaphylatoxin C3a (which is further metabolized into C3desArg) and C3b, leading to the formation of C5 convertase and the subsequent formation of the terminal complement effector C5b-9. The latter either induces cell lysis and necrotic cell death or activates signalling pathways that drive the production of inflammatory molecules [42] . Here we showed the presence of C5b-9 in OA synovial membrane and cartilage and, as revealed by the cartilage immunohistochemistry, its pericellular location similar to that of adipsin. The presence of adipsin in the upper layer of the cartilage matrix and its significantly higher levels in OA matrix probably result from SF diffusion. The very superficial matrix and pericellular presence of C5b-9 in normal cartilage likely reflects the low production levels of this complement factor in normal synovial membrane/ fluid [42] .
Further investigation of the in vivo adipsin contribution to the progression of OA was done using an OA model in adipsin-deficient mice. Data first showed, as previously reported [15, 21] , that these mice have no developmental abnormality. Adipsin-deficient mice have been previously shown to lack C3adesArg [43] , a complement component known to be up-regulated in human OA SF [42] . Wild type and adipsin-deficient mice were subjected to DMM surgery, which is a commonly used model to study OA [44] . Data from the DMM mice showed that the adipsindeficient mice presented a better synovial membrane and cartilage structure than the wild type. This is substantiated in the cartilage by the reduced production of degradation and proteolytic factors. Moreover, the complement factor C5b-9 and associated markers MCP-1 and CXCL1 [42, 45] were also significantly reduced. These results thus corroborate the role of the adipsinC3desArg axis as regulator of degradation factors. Of note, C5b-9 is not seen in the mouse cartilage matrix; this could be related to the fact that, in this OA mouse model, inflammation of the synovial membrane is not the major feature [33, 46] , and thus there is lower production compared with the human tissue, resulting in less diffusion of the complement factors from the SF.
Further analysis of the direct effect of adipsin and the alternative complement pathway could be done to some extent in vitro on chondrocytes. However, in situ investigation of the cartilage for the study of adipsin is better suited for a complement factor that heavily interacts with and influences other extracellular matrix macromolecules as well as chondrocyte metabolism.
Data from this study thus demonstrated that high in vivo adipsin levels are associated with greater lateral cartilage volume loss over time. Moreover, findings implicate a role for adipsin in OA synovial membrane and cartilage, through the activation of the alternative complement pathway. In conclusion, this study not only highlights the clinical relevance of adipsin, but provides support for adipsin as a valuable biomarker for OA and also as a potential therapeutic target for this disease. necessarily reflect the opinions or views of the OAI investigators, the NIH or the private funding partners. 
